2018-01-YS-ECI AWARD WINNER ALEXEY RUMYANTSEV
Rumyantsev Aleхеy Aleksandrovich (N. N. Blokhin National Medical Research Centre of Oncology)
Phase II randomized trial to evaluate efficacy of olanzapine with short-acting 5HT3 inhibitors in chemotherapy-induced nausea & vomiting (CINV) prophylaxis
232 500 rubles.
Accompanying therapy in oncology plays a no less important role than antitumor therapy itself, allowing to fully carry out the latter while maintaining patients’ quality of life. One of the most common chemotherapy adverse events – the development of nausea and vomiting – can have a truly devastating effect on the lives of patients and their relatives. Modern medicine has made great strides in the prevention of these complications. Unfortunately, many of these achievements are inaccessible to patients given the current realities of our healthcare system because of their high cost.
Our attention was drawn to the possibility of using an effective, cheap and affordable drug to prevent this complication of chemotherapy – olanzapine, which is already successfully used in Europe and the US for treatment and prevention of nausea and vomiting associated with chemotherapy. However, the currently recommended combination regimen reduces the availability of this therapy and is associated with the development of a distinct sedative side effect. We believe that dose optimization and the combination of olanzapine with other antiemetics may become a new standard for accompanying therapy. The purpose of our study is to develop a new regimen for the prevention of nausea and vomiting, which will improve the quality of everyday life of cancer patients.